Combination Therapy Targets Latent Reservoir of HIV | BIDMC

Combination Therapy Targets Latent Reservoir of HIV | BIDMC

Broadly Neutralizing Antibody Treatment Delays HIV Rebound, May Target Viral Reservoir in Monkeys

After receiving a course of antiretroviral therapy for their HIV-like infection, monkeys infused with a broadly neutralizing antibody to HIV combined with an immune stimulatory compound suppressed the virus for as many as six months without additional treatment, according to scientists supported in part by NIH. The therapy may have targeted the viral reservoir—populations of long-lived, latently infected cells that harbor the virus and that lead to resurgent viral replication when suppressive therapy is discontinued. The work, reported today in Nature, builds on data originally reported at the 25th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston in March 2018.